Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program.
de Moura A, Vuagnat P, Renouf B, Pierga JY, Loirat D, Vaflard P, Lafayolle de la Bruyère C, Chaumard-Billotey N, Hajjaji N, Ladoire S, Dabakuyo S, Patsouris A, Frenel JS, Nicolai V, Alexandre M, Dohollou N, Grenier J, Bourien H, Bidard FC. de Moura A, et al. Among authors: vuagnat p. Sci Rep. 2023 Aug 18;13(1):13427. doi: 10.1038/s41598-023-40569-9. Sci Rep. 2023. PMID: 37596388 Free PMC article.
Effectiveness of electronic patient reporting outcomes, by a digital telemonitoring platform, for prostate cancer care: the Protecty study.
Helissey C, Parnot C, Rivière C, Duverger C, Schernberg A, Becherirat S, Picchi H, Le Roy A, Vuagnat P, Pristavu R, Vanquaethem H, Brureau L. Helissey C, et al. Among authors: vuagnat p. Front Digit Health. 2023 May 8;5:1104700. doi: 10.3389/fdgth.2023.1104700. eCollection 2023. Front Digit Health. 2023. PMID: 37228301 Free PMC article.
Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score.
Pierro M, Baldini C, Auclin E, Vincent H, Varga A, Martin Romano P, Vuagnat P, Besse B, Planchard D, Hollebecque A, Champiat S, Marabelle A, Michot JM, Massard C, Mezquita L. Pierro M, et al. Among authors: vuagnat p. Cancers (Basel). 2022 Oct 17;14(20):5078. doi: 10.3390/cancers14205078. Cancers (Basel). 2022. PMID: 36291861 Free PMC article.
PALLIA 10 score in phase I cancer studies.
Ouali K, Mateus C, Laparra A, Martin Romano P, Sampetrean A, Vuagnat P, Varga A, Champiat S, Verlingue L, Geraud A, Marabelle A, Hollebecque A, Gazzah A, Bahleda R, Postel Vinay S, Michot JM, Bernard-Tessier A, Bayle A, Ribrag V, Soria JC, Scotte F, Massard C, Pavliuc E, Baldini C. Ouali K, et al. Among authors: vuagnat p. BMJ Support Palliat Care. 2022 Aug 30:bmjspcare-2022-003601. doi: 10.1136/spcare-2022-003601. Online ahead of print. BMJ Support Palliat Care. 2022. PMID: 36041820
Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.
Nebot-Bral L, Hollebecque A, Yurchenko AA, de Forceville L, Danjou M, Jouniaux JM, Rosa RCA, Pouvelle C, Aoufouchi S, Vuagnat P, Smolenschi C, Colomba E, Leary A, Marabelle A, Scoazec JY, Cassard L, Nikolaev S, Chaput N, Kannouche P. Nebot-Bral L, et al. Among authors: vuagnat p. J Immunother Cancer. 2022 Jul;10(7):e005059. doi: 10.1136/jitc-2022-005059. J Immunother Cancer. 2022. PMID: 35896284 Free PMC article.
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
Baldini C, Danlos FX, Varga A, Texier M, Halse H, Mouraud S, Cassard L, Champiat S, Signolle N, Vuagnat P, Martin-Romano P, Michot JM, Bahleda R, Gazzah A, Boselli L, Bredel D, Grivel J, Mohamed-Djalim C, Escriou G, Grynszpan L, Bigorgne A, Rafie S, Abbassi A, Ribrag V, Postel-Vinay S, Hollebecque A, Susini S, Farhane S, Lacroix L, Parpaleix A, Laghouati S, Zitvogel L, Adam J, Chaput N, Soria JC, Massard C, Marabelle A. Baldini C, et al. Among authors: vuagnat p. J Exp Clin Cancer Res. 2022 Jul 7;41(1):217. doi: 10.1186/s13046-022-02423-0. J Exp Clin Cancer Res. 2022. PMID: 35794623 Free PMC article. Clinical Trial.
56 results